Nike Inc vs Stryker Corporation — how do they compare? Nike Inc trades at $37.13 (market cap $56.52B), while Stryker Corporation trades at $276.5 (market cap $106.03B). The key difference: Stryker Corporation is the larger of the two by market cap, and Nike Inc pays the higher dividend (4.3%). Which is the better fit depends on your goals.
| NKE | SYK | |
|---|---|---|
Market Cap | $56.52B | $106.03B |
Volume | 8,887,180 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $74.57 | $388.79 |
52-Week Low | $37.35 | $275.39 |
Enterprise Value | $58.53B | $117.50B |
Dividend Yield | 4.3% | 1.27% |
Signals from Pluang's Aura AI — not financial advice
Nike (NKE) trades at $37.35, down 2.73% amid bearish technical signals and recent earnings volatility. The stock shows strong profitability metrics with 42.91% gross margins and 22.14% ROE, but faces revenue pressure with FY2025 sales declining to $46.31B. Analyst consensus remains positive with a $49.81 price target, though technical indicators signal caution with 17 sell signals versus 3 buy signals.
Nike's investment case balances strong brand equity and recent earnings beats against China market challenges and inventory pressures. The stock offers 33% upside to consensus targets but requires successful execution of the 'Win Now' turnaround strategy to overcome near-term headwinds in key markets.
Stryker (SYK) is trading at $276.43, down 8.81% over 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Strong fundamentals include a net income margin of 14.43% and ROE of 16.51%, though valuation ratios like a P/E of 28.65 are elevated. Recent news includes a securities fraud investigation announcement and the launch of an FDA-cleared surgical app for Apple Vision Pro.
The outlook for SYK is supported by solid profitability and growth initiatives like acquisitions and product launches, but near-term risks include the fraud investigation and competitive pressures. Analyst consensus is strongly bullish with a $376 price target, suggesting significant upside potential if the company navigates current challenges successfully.
Trailing returns across standard periods
Latest headlines on both assets
NIKE, Inc. designs, develops, and markets athletic footwear, apparel, equipment, and accessory products for men, women, and children. The Company sells its products worldwide to retail stores, through its own stores, subsidiaries, and distributors.
Read more on NKE →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →